X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2502) 2502
Publication (189) 189
Newsletter (61) 61
Book Review (35) 35
Magazine Article (21) 21
Book Chapter (9) 9
Conference Proceeding (6) 6
Dissertation (4) 4
Newspaper Article (3) 3
Data Set (2) 2
Trade Publication Article (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
risedronate (1785) 1785
humans (1624) 1624
female (1314) 1314
osteoporosis (1302) 1302
index medicus (971) 971
etidronic acid - analogs & derivatives (945) 945
risedronate sodium (921) 921
alendronate (886) 886
aged (874) 874
middle aged (785) 785
endocrinology & metabolism (705) 705
bone density conservation agents - therapeutic use (696) 696
bisphosphonates (673) 673
male (607) 607
etidronic acid - therapeutic use (590) 590
postmenopausal osteoporosis (518) 518
bone density - drug effects (496) 496
osteoporosis - drug therapy (494) 494
diphosphonates - therapeutic use (491) 491
osteoporosis, postmenopausal - drug therapy (482) 482
fractures (480) 480
women (478) 478
postmenopausal women (474) 474
orthopedics (427) 427
drug therapy (373) 373
aged, 80 and over (368) 368
risk (366) 366
risk factors (365) 365
bone density conservation agents - administration & dosage (357) 357
bone-mineral density (354) 354
vertebral fractures (347) 347
animals (336) 336
treatment outcome (325) 325
bone density (322) 322
rheumatology (311) 311
medicine & public health (307) 307
prevention (294) 294
bisphosphonate (288) 288
alendronate - therapeutic use (283) 283
etidronic acid - administration & dosage (283) 283
randomized-trial (273) 273
diphosphonates - administration & dosage (268) 268
therapy (268) 268
bones (266) 266
zoledronic acid (266) 266
bone mineral density (264) 264
medicine, general & internal (260) 260
density (242) 242
bone density conservation agents - adverse effects (240) 240
etidronic acid - pharmacology (231) 231
health aspects (229) 229
hip fracture (227) 227
research (227) 227
adult (224) 224
double-blind (224) 224
care and treatment (223) 223
endocrinology (223) 223
fractures, bone - prevention & control (213) 213
pharmacology & pharmacy (204) 204
analysis (194) 194
double-blind method (193) 193
bone density conservation agents - pharmacology (192) 192
bone (189) 189
nonvertebral fractures (189) 189
drug administration schedule (185) 185
dosage and administration (184) 184
administration, oral (181) 181
diphosphonates - adverse effects (177) 177
etidronic acid - adverse effects (175) 175
rats (175) 175
time factors (167) 167
diphosphonates (163) 163
mineral density (159) 159
fracture (157) 157
vertebral fracture (152) 152
diphosphonates - pharmacology (145) 145
alendronate - administration & dosage (144) 144
osteoporosis - prevention & control (141) 141
osteoporosis, postmenopausal - complications (141) 141
medicine, research & experimental (139) 139
phosphonates (139) 139
efficacy (134) 134
randomized controlled trials as topic (133) 133
spinal fractures - prevention & control (127) 127
trial (127) 127
risedronic acid (125) 125
complications and side effects (124) 124
fracture risk (124) 124
bone and bones - drug effects (118) 118
bone remodeling - drug effects (116) 116
osteoporosis - complications (116) 116
ibandronate (114) 114
management (113) 113
retrospective studies (113) 113
dose-response relationship, drug (111) 111
internal medicine (110) 110
turnover (109) 109
follow-up studies (108) 108
clinical trials (107) 107
raloxifene (105) 105
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2385) 2385
German (75) 75
Japanese (43) 43
Spanish (30) 30
French (21) 21
Turkish (8) 8
Korean (7) 7
Portuguese (7) 7
Croatian (5) 5
Dutch (5) 5
Danish (3) 3
Czech (2) 2
Hungarian (2) 2
Lithuanian (2) 2
Polish (2) 2
Slovak (2) 2
Ukrainian (2) 2
Chinese (1) 1
Finnish (1) 1
Norwegian (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Osteoporosis International, ISSN 0937-941X, 1/2016, Volume 27, Issue 1, pp. 21 - 31
We used bone turnover markers to identify women who responded to bisphosphonate treatment for osteoporosis. Response was more likely with alendronate and... 
Bisphosphonate | Medicine & Public Health | Orthopedics | Variability | Rheumatology | Postmenopausal osteoporosis | Bone turnover markers | Endocrinology | BIOCHEMICAL MARKERS | RANDOMIZED-TRIAL | ELDERLY-WOMEN | RISK | FRACTURE INTERVENTION TRIAL | ALENDRONATE THERAPY | MINERAL DENSITY | VERTEBRAL FRACTURES | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | RISEDRONATE | Bone Density - physiology | Humans | Middle Aged | Premenopause - blood | Reference Values | Bone Remodeling - physiology | Bone Remodeling - drug effects | Alendronate - therapeutic use | Risedronate Sodium - therapeutic use | Risedronate Sodium - administration & dosage | Aged, 80 and over | Diphosphonates - therapeutic use | Risedronate Sodium - pharmacology | Adult | Female | Lumbar Vertebrae - physiopathology | Administration, Oral | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Diphosphonates - administration & dosage | Biomarkers - blood | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Alendronate - pharmacology | Osteoporosis, Postmenopausal - physiopathology | Aged | Diphosphonates - pharmacology | Alendronate - administration & dosage | Osteoporosis | Complications and side effects | Patient outcomes | Phosphonates | Development and progression | Postmenopausal women | Research | Health aspects | Bone density | Drug therapy | Menopause | Clinical outcomes
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 06/2016, Volume 506, Issue 1-2, pp. 253 - 261
Journal Article
Osteoporosis International, ISSN 0937-941X, 12/2014, Volume 25, Issue 12, pp. 2729 - 2741
We compared the effects of oral alendronate, ibandronate and risedronate on the central and peripheral skeleton over 2 years. We report differences in effect... 
TRIO study | Medicine & Public Health | Treatment effects | Orthopedics | Rheumatology | Peripheral skeleton | Oral bisphosphonates | Densitometry | Postmenopausal osteoporosis | Endocrinology | METAANALYSIS | BONE-MINERAL DENSITY | RISK | IBANDRONATE | WOMEN | MONITORING ALENDRONATE THERAPY | VERTEBRAL FRACTURES | ENDOCRINOLOGY & METABOLISM | QUANTITATIVE ULTRASOUND | RISEDRONATE | Humans | Middle Aged | Risedronate Sodium - adverse effects | Alendronate - therapeutic use | Risedronate Sodium - therapeutic use | Risedronate Sodium - administration & dosage | Aged, 80 and over | Diphosphonates - therapeutic use | Absorptiometry, Photon - methods | Adult | Female | Diphosphonates - adverse effects | Lumbar Vertebrae - physiopathology | Bone Density Conservation Agents - adverse effects | Administration, Oral | Bone Density Conservation Agents - therapeutic use | Diphosphonates - administration & dosage | Lumbar Vertebrae - drug effects | Bone Density Conservation Agents - administration & dosage | Hip Joint - drug effects | Osteoporosis, Postmenopausal - drug therapy | Upper Extremity - physiopathology | Alendronate - adverse effects | Bone Density - drug effects | Medication Adherence | Hip Joint - physiopathology | Lower Extremity - physiopathology | Osteoporosis, Postmenopausal - physiopathology | Aged | Alendronate - administration & dosage | Osteoporosis | Care and treatment | Dosage and administration | Comparative analysis | Patient outcomes | Diphosphonates | Bone density | Skeletal system | Drug therapy | Medical treatment
Journal Article
Journal of Comparative Pathology, ISSN 0021-9975, 01/2015, Volume 152, Issue 1, pp. 68 - 68
Journal Article
Atencion Primaria, ISSN 0212-6567, 05/2016, Volume 48, Issue 5, pp. 316 - 324
Objective: To assess the persistence of treatment with monthly risedronate and know the reasons of persistence and nontherapeutic persistence and the profile... 
Risedronate | Osteoporosis | Medication persistence
Journal Article
Osteoporosis International, ISSN 0937-941X, 5/2016, Volume 27, Issue 5, pp. 1701 - 1708
In a retrospective analysis of 208 osteoporotic patients followed during a bisphosphonate holiday, lower body weight and risedronate use were associated with a... 
Osteoporosis | Bisphosphonate | Drug holiday | Medicine & Public Health | Orthopedics | Rheumatology | Bone mineral density | Fracture | Endocrinology | ZOLEDRONIC ACID TREATMENT | WEIGHT-LOSS | RANDOMIZED-TRIAL | EXTENSION | DISCONTINUATION | ALENDRONATE THERAPY | WOMEN | POSTMENOPAUSAL OSTEOPOROSIS | VERTEBRAL FRACTURES | ENDOCRINOLOGY & METABOLISM | RISEDRONATE | Humans | Middle Aged | Osteoporosis, Postmenopausal - complications | Male | Osteoporosis - drug therapy | Osteoporotic Fractures - etiology | Alendronate - therapeutic use | Risedronate Sodium - therapeutic use | Risedronate Sodium - administration & dosage | Diphosphonates - therapeutic use | Risedronate Sodium - pharmacology | Female | Retrospective Studies | Osteoporotic Fractures - physiopathology | Osteoporosis - physiopathology | Risk Assessment | Osteoporotic Fractures - prevention & control | Bone Density Conservation Agents - therapeutic use | Diphosphonates - administration & dosage | Bone Density Conservation Agents - administration & dosage | Withholding Treatment | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Osteoporosis - complications | Alendronate - pharmacology | Osteoporosis, Postmenopausal - physiopathology | Aged | Body Weight - physiology | Diphosphonates - pharmacology | Alendronate - administration & dosage | Complications and side effects | Care and treatment | Fractures | Patient outcomes | Bones | Research | Density | Risk factors | Alendronic acid | Femur | Risedronic acid | Body weight | Spine (lumbar) | Hormone replacement therapy | Bone density | Trends | Bisphosphonates | Hip
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 10/2015, Volume 32, Issue 10, pp. 3149 - 3158
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9902, pp. 1424 - 1432
Journal Article